Abstracts Archive - Page 7 of 2616 - ACR Meeting Abstracts

Abstract Number: 011 • 2026 Pediatric Rheumatology Symposium
Lung Transplant for Pediatric Dermatomyositis Patients with Interstitial Lung Disease: A Single-Center Experience
Alison Brittain¹, Elizabeth Murray², Ivana Stojkic³, Vidya Sivaraman⁴, Katelyn Krivchenia¹, Stephen Kirkby³ and Shoghik Akoghlanian⁵, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital/The Ohio State University, Columbus, OH, ³Nationwide Children's Hospital, ⁴Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁵Nationwide Childrens Hospital, Columbus, OH
Background/Purpose: Interstitial lung disease (ILD) is a feared complication of several pediatric rheumatic diseases, particularly dermatomyositis. Lung transplant is often considered as a last resort in these patients, which can lead to delayed transplant assessment…
Abstract Number: 052 • 2026 Pediatric Rheumatology Symposium
Case Series: Treatment of Refractory Lung Disease in Systemic Juvenile Idiopathic Arthritis with Cyclophosphamide and Rituximab Combination Therapy
William Freeman¹, Randy Cron² and Eileen Rife³, ¹Zucker School of Medicine at Hofstra University, Bellerose, NY, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama Birmingham, Vestavia Hills, AL
Background/Purpose: Systemic juvenile idiopathic arthritis-associated lung disease (sJIA-LD) is a rare, potentially fatal complication of sJIA, often accompanied by pulmonary hypertension (PH) and macrophage activation…
Abstract Number: 001 • 2026 Pediatric Rheumatology Symposium
Longitudinal Cardiovascular Profiles of Youth with Childhood-onset Systemic Lupus Erythematosus
Joyce Chang¹, Gabrielle Alonzi², Michael Ferguson³, Andrea Knight⁴, Jane Newburger⁵, Pamela Weiss⁶, Mary Beth Son² and Karen Costenbader⁷, ¹Boston Children's Hospital, Newton, MA, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, MA, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵Boston Childen's Hospital, Boston, MA, ⁶Childrens Hospital of Philadelphia, Philadelphia, PA, ⁷Brigham and Women's Hospital/ Harvard Medical School, BOSTON, MA
Background/Purpose: The cumulative impact of childhood-onset systemic lupus erythematosus (cSLE) on cardiovascular damage begins at disease onset. We sought to characterize longitudinal cardiovascular profiles of…
Abstract Number: 088 • 2026 Pediatric Rheumatology Symposium
Demographics and Clinical Features of Deficiency of adenosine deaminase 2: A Large Quaternary Single Center Experience
Busra Dalgic¹, Marietta DeGuzman² and Cagri Yildirim-Toruner³, ¹Baylor College of Medicine, ²Baylor College of Medicine, Houston, TX, ³Texas Children's Hospital/ Baylor College of Medicine, Houston, TX
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2), described in 2014, is characterized by intermittent fevers, early-onset lacunar strokes, livedoid rash, hepatosplenomegaly, systemic vasculopathy, and/or immunodeficiency.…
Abstract Number: 063 • 2026 Pediatric Rheumatology Symposium
Improving Pediatric Lupus Patient Education: Patient and Provider Needs Assessment
Madison Hoenle¹, Melissa Argraves² and Alysha Taxter³, ¹Nationwide Children's Hospital Pediatric Residency, Columbus, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Nationwide Children's, Columbus, OH
Background/Purpose: Children arrive at a lupus diagnosis with varying physical, emotional, and cognitive maturity, which evolves throughout their time in pediatric care. These differences influence…
Abstract Number: 086 • 2026 Pediatric Rheumatology Symposium
APOL1 Focal Segmental Glomerulosclerosis Requiring Renal Transplant, the Burden of Childhood onset Autoimmune and Autoinflammatory Disease
Andrew Zeft¹, Charles Kwon², Raed Bou Matar², Xiangling Wang² and Sirada Panupattanapong¹, ¹Department of Pediatric Rheumatology, Cleveland Clinic Children's Hospital, Cleveland, OH, ²Cleveland Clinic
Background/Purpose: Apolipoprotein L1 (APOL1) mediated kidney disease with focal segmental glomerulosclerosis (FSGS) is a severe form of renal disease with risk of progressing towards end…
Abstract Number: 072 • 2026 Pediatric Rheumatology Symposium
SOCS1 Haploinsufficiency: Functional Evidence Supporting an Expanded Clinical Phenotype
Andrew Zeft¹, Pui Lee², Jaime Vondenberg³, Casey Rimland⁴, Rachel Weng⁵ and Harry Lesmana⁶, ¹Department of Pediatric Rheumatology, Cleveland Clinic Children's Hospital, Cleveland, OH, ²Boston Children's Hospital, Newton, MA, ³Cleveland Clinic, ⁴Brigham and Women's Hospital, ⁵Boston Children's Hospital, ⁶Department of Genetics and Genomics, Department of Pediatric Hematology/Oncology, Cleveland Clinic Children's Hospital
Background/Purpose: Insufficiency of Suppressor of Cytokine Signaling 1 (SOCS1) typically manifests with autoimmune features. Recently, some cases have also shown autoinflammatory traits such as recurrent…
Abstract Number: 024 • 2026 Pediatric Rheumatology Symposium
Therapeutic Plasma Exchange in Pediatric Autoimmune Encephalitis
Ingrid Kattan¹, PAOLA LARA HERERA², ENRIQUE FAUGIER FUENTES³, Candy Leon, MD³, Andrea Sanchez³, VIanca De Leon³ and Enrique Juarez³, ¹HOSPITAL INFANTIL DE MEXICO FEDERICO GOMEZ, Ciudad de Mxico, Mexico, ²HOSPITAL INFANTIL DE MEXICO FEDERICO GOMEZ, MEXICO CITY, Mexico, ³HOSPITAL INFANTIL DE MEXICO FEDERICO GOMEZ
Background/Purpose: Autoimmune encephalitis (AE) is a severe neuroinflammatory disorder mediated by antibodies against neuronal receptors. Therapeutic plasma exchange (TPE) can remove autoantibodies, immune complexes, and…
Abstract Number: 093 • 2026 Pediatric Rheumatology Symposium
HOW DO WE HANDLE STILL’S DISEASE? REAL-LIFE CLINICIANS’ CHOICES FROM THE METAPHOR PROJECT WORLDWIDE SURVEY
Francesco Baldo¹, Greta Rogani², Claudia Bracaglia³, Dirk Foell⁴, Marco Gattorno⁵, Jordi Anton⁶, Marija Jelusic⁷, Paul Brogan⁸, Scott Canna⁹, Randy Cron¹⁰, Fabrizio De Benedetti¹¹, Alexei Grom¹², Merav Heshin Bekenstein¹³, AnnaCarin Horne¹⁴, Raju Khubchandani¹⁵, Mao Mizuta¹⁶, Seza zen¹⁷, Pierre Quartier Dit Maire¹⁸, Angelo Ravelli¹⁹, Nicolino Ruperto²⁰, Masaki Shimizu²¹, Grant Schulert¹², Rashmi Sinha²², Christiaan Scott²³, Joost Swart²⁴, Bruno Fautrel²⁵, Sebastiaan Vastert² and Francesca Minoia²⁶, ¹UOC Reuamtologia Pediatrica-ASST-Pini-CTO.it, Italy, ²University Medical Center Utrecht, Utrecht, Netherlands, ³Division of Rheumatology Ospedale Pediatrico Bambino Gesu' IRCCS, Roma, Italy, Rome, Rome, Italy, ⁴University Hospital Muenster, Muenster, Germany, ⁵Division of Rheumatology and Autoinflammatory Diseases, IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genova, Italy, ⁶Hospital Sant Joan de Du. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁷University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁸UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰University of Alabama at Birmingham, Birmingham, AL, ¹¹Bambino Gesu Children's Hospital, Rome, Rome, Italy, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Tel Aviv Medical Center Israel, Binyamina, Israel, ¹⁴Karolinska University Hospital, Sollentuna, Sweden, ¹⁵SRCC Children's Hospital, Mumbai, India, India, ¹⁶Department of Paediatric Rheumatology, Hyogo Prefectural Kobe Children's Hospital, Kanazawa, Japan, Kanazawa, Japan, ¹⁷Hacettepe University Medical Faculty, Ankara, Turkey, ¹⁸Necker hospital, Paris Cedex ¹⁵, France, ¹⁹IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ²⁰Università Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Italy, ²¹Tokyo Medical and Dental University, Tokyo, Japan, Kanazawa, Japan, ²²Systemic JIA Foundation, Los Altos, CA, ²³Childrens Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ²⁴Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, ²⁵Sorbonne University - APHP, Paris, France, ²⁶Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
Background/Purpose: Despite continuous improvement in care and the recent update of international recommendations, relevant discrepancies in the approach to Still’s disease (SD) still exists.The study…
Abstract Number: 095 • 2026 Pediatric Rheumatology Symposium
Rheum2Fake: Lessons from Severe Nutritional Deficiencies
Helina Maharjan¹, Barbara Ostrov², Emily Kong³ and Suhas Ganguli³, ¹Albany Med Health System, ²Albany Medical College, Slingerlands, NY, ³Albany Medical College
Background/Purpose: Micronutrient deficiencies can lead to protean clinical manifestations, including those mimicking autoimmune or auto-inflammatory diseases, contributing to misdiagnosis, delay in treatment, and even unnecessary immunosuppression. Individuals with…
Abstract Number: 097 • 2026 Pediatric Rheumatology Symposium
Evaluating Associations between Diffusion Tensor Imaging Metrics and Cognitive Function in Youth with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Jin Xuan Zhou¹, Diana Valdes Cabrera¹, Oscar Mwizerwa², Asha Jeyanathan³, Lawrence Ng⁴, Birgit-Ertl Wagner⁵, Helen Branson⁵, Adrienne Davis⁵, Deborah Levy¹, Linda Hiraki¹ and Andrea Knight⁶, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, The Hospital for Sick Children, Moncton, NB, Canada, ³Hospital for Sick Children, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁵The Hospital for Sick Children, ⁶Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is an inflammatory autoimmune disease that can lead to cognitive dysfunction (CD) across multiple domains. While conventional magnetic resonance imaging can detect brain abnormalities in cSLE, these findings do not always associate with clinical symptoms. Diffusion…
Abstract Number: 007 • 2026 Pediatric Rheumatology Symposium
Subtle Signs, Severe Consequences: Clinical profile of infants with giant coronary aneurysms compared to those with normal coronaries. A multicentric retrospective analysis of infants with Kawasaki disease
Abhay Shivpuri¹, manjari Agarwal² and sujata Sawhney³, ¹Neoclinic Children's Hospital, Jaipur, Rajasthan, India, ²Sir Ganga Ram Hospital, NEW DELHI, Delhi, India, ³Sir Ganga Ram Hospital, Sector ³⁷ noida, Uttar Pradesh, India
Background/Purpose: Kawasaki disease (KD) is a systemic medium vessel vasculitis that is predominantly a clinical diagnosis as defined by the American Heart Association (AHA). KD…
Abstract Number: 004 • 2026 Pediatric Rheumatology Symposium
Barriers and Facilitators to Teratogenicity Knowledge and Application among Adolescents and Young Adults with Rheumatic Disease
Brittany Huynh¹, Elizabeth Pfeiffer² and Stacey Tarvin³, ¹University of Alabama at Birmingham, ²Rhode Island College, ³Riley Hospital for Children at Indiana University, Indianapolis, IN
Background/Purpose: Prior studies demonstrate low levels of teratogenicity knowledge among adolescents and young adults (AYAs) with rheumatic disease. This study sought to describe barriers and…
Abstract Number: 026 • 2026 Pediatric Rheumatology Symposium
Treatment strategies for articular flares in JIA patients receiving biologic therapy
Jonatan zalcman, Yoel Levinsky, Liora Harel, Ruth Livny and gil amarilyo, Schneider Children's medical center of Israel
Background/Purpose: Biologic agents form the cornerstone of therapy for Juvenile Idiopathic Arthritis (JIA); however, the optimal management of flares that occur during ongoing treatment remains…
Abstract Number: 085 • 2026 Pediatric Rheumatology Symposium
Outcomes of Oligoarticular Juvenile Idiopathic Arthritis Patients Treated with Intra-articular Glucocorticoids: Can We Predict Successful Treatment?
Andrew Kung¹, Kimberly Hays¹, Lisabeth Scalzi², Catherine Bingham³, Ferris Troy Yu Asensi⁴ and Timothy Hahn¹, ¹Penn State Childrens Hospital, Hershey, PA, ²Penn State Childrens Hospital, Hummelstown, PA, ³Penn State Childrens Hospital, ⁴Penn State Childrens Hospital, Jacksonville, FL
Background/Purpose: Intra-articular glucocorticoids (IAGCs) are a common first-line therapy for patients with oligoarticular juvenile arthritis. Limited data exist on rates and predictors of treatment escalation…

« Previous Page
1
…
5
6
7
8
9
…
2616
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].